Corbett et al., 1995 - Google Patents
Tumor models and the discovery and secondary evaluation of solid tumor active agentsCorbett et al., 1995
- Document ID
- 5643941089272898900
- Author
- Corbett T
- Valeriote F
- Lorusso P
- Polin L
- Panchapor C
- Pugh S
- White K
- Knight J
- Demchik L
- Jones J
- Jones L
- Lowichik N
- Biernat L
- Foster B
- Wozniak A
- Lisow L
- Valdivieso M
- Baker L
- Leopold W
- Sebolt J
- Bissery M
- Mattes K
- Dzubow J
- Rake J
- Perni R
- Wentland M
- Coughlin S
- Shaw J
- Liversidge G
- Liversidge E
- Bruno J
- Sarpotdar P
- Moore R
- Patterson G
- Publication year
- Publication venue
- International journal of pharmacognosy
External Links
Snippet
Each independently arising tumor is a separate and unique biologic entity with its own unique histologic appearance, biologic behavior, and drug response profile. Thus, in drug discovery, no single tumor has been a perfect predictor for any other tumor. For this reason …
- 206010028980 Neoplasm 0 title abstract description 220
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulfur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corbett et al. | Tumor models and the discovery and secondary evaluation of solid tumor active agents | |
| US3723476A (en) | 1-hydrocarbylamino-3-(ortho-furylmethyloxyphenoxy or tetrahydrofurylmethyloxy-phenoxy)-2-propanol compounds | |
| US6589941B1 (en) | Utilization of 5′ substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions | |
| Jaffe | Malignant lymphomas: pathology of hepatic involvement | |
| DE69202243T2 (en) | 2,4-diaminoquinazoline derivatives to increase the anti-tumor effect. | |
| CA2111902A1 (en) | Antitumor compositions and methods of treatment | |
| DE69426423T2 (en) | NEW INHIBITORS OF URIDINE PHOSPHORYLASE (UrdPase) AND DIHYDROURACILDEHYDROGENASE (DHUDase) | |
| DE69929464T2 (en) | CYCLIC POLYAMINES FOR THE TREATMENT OF THROMBOCYTOPENIA | |
| Borthakur et al. | Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy | |
| JP2002523403A (en) | Quinazoline derivatives | |
| EP0812319B9 (en) | 2-arylbenzazole compounds | |
| DE10013715A1 (en) | New aryl-guanidines with side-chains comprising hydrogen bond donor and acceptor groups, are selective urokinase plasminogen activator inhibitors useful for treating tumors or tumor metastasis | |
| DE69528103T2 (en) | Use of riminophenazine for the treatment of MDR resistance | |
| DeVita et al. | Preliminary clinical studies with ibenzmethyzin | |
| ES2967929T3 (en) | Methods of treatment of hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 ,3-dione | |
| DE9290039U1 (en) | Pyrimidine derivatives to improve anti-tumor activity | |
| US4650801A (en) | Anti-cancer compositions for delivering 5-fluorouracil | |
| Fallon et al. | Correlations of the biochemical and clinical effects of 6-azauridine in patients with leukemia | |
| JPS62501632A (en) | 4-Substituted-6-arylpyrimidine compounds | |
| US20190169171A1 (en) | Fluorine- and/or deuterium-containing compounds for treating non-small cell lung cancer and related diseases | |
| Peters et al. | The experimental chemotherapy of leishmaniasis, V: The activity of potential leishmanicides against ‘L. infantum LV9’in NMRI mice | |
| Sabaawy et al. | Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells | |
| EP0290558A1 (en) | Antifolate agents. | |
| Thambi et al. | STI571 (imatinib mesylate): the tale of a targeted therapy | |
| DE202015009594U1 (en) | New dimers of cytidine derivatives |